That's because the goal of the company was to evaluate the use of nirogacestat for the treatment of adults with relapsed/refractory ovarian granulosa cell tumors (OvGCTs) in a phase 2 open-label ...

The drug is also in mid-stage clinical development for ovarian granulosa cell tumors, a rare type of ovarian cancer that currently has no FDA-approved therapies. Through partnerships, the twice ...

is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. Shares of SWTX stock traded down $0.40 on Friday ...

is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. Shares of NASDAQ:SWTX traded down $0.21 during ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors ...

USC researchers have developed an innovative type of cancer-fighting immune cell, the EchoBack CAR T-cell, that uses focused ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Emactuzumab demonstrated a 71% objective response rate, rapid tumor reduction, and manageable side effects in early trials. Emactuzumab has received fast track designation from the U.S. FDA for ...